AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04515615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
Study NCT04515615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130 mg/m\^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
Study NCT04515615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur gimeracil oteracil potassium capsule
Description: Tegafur gimeracil oteracil potassium capsule: 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
Study NCT02188264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT02188264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02188264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02188264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT03392064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 119
Description: Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
Study NCT04377100 — intervention group
Intervention type: BEHAVIORAL
Intervention: Computer task questionnaires
Description: MH COVID-19 Adult, MASQ-SF, STAI, ACS, Hollingshead, DSM XC, PMHC, AUDIT, debriefing questionnaire, and finger-tapping task
Study NCT05595707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert-Guided Early Tracheostomy
Description: Patients judged to be at moderate to high risk of prolonged ventilation(26, 27) were those who had chronic respiratory failure, advanced Effectiveness of an Expert-Guided Early Tracheostomy Pathway Page 6/27 age, thrombocytopenia or coagulopathy, persistent vasopressor shock, requirement for renal replacement therapy, an admission trauma diagnosis amongst other criteria, were included. In the absence of these criteria, a consensus for low risk of prolonged MV was reached. Early PDT, within the first 7 days from intubation, was recommended for patients with a moderate/high risk of prolonged MV (Early Group). Continued MV by ETT was recommend for low-risk patients with the potential for delayed PDT in the event of delayed weaning and liberation (Late Group).
Study NCT01570413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Pelvic Exam
Description: Will not receive pelvic examination.
Study NCT01570413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Examination
Description: Pelvic examination will be performed.
Study NCT01003808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMF-001
Description: 100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
Study NCT02086175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Study NCT02086175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT04678895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.
Study NCT04678895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone matched placebo capsule.
Study NCT05313984 — intervention group
Intervention type: DEVICE
Intervention: Sacral neuromodulation
Description: Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator.
Study NCT04934800 — intervention group
Intervention type: DRUG
Intervention: Cladribine
Description: No intervention will be administered as a part of this study. Participants who had switched from first-line DMD treatments to treatment with cladribine tablets in routine clinical practice will be assessed for 2 years in this study.
Study NCT01708408 — intervention group
Intervention type: GENETIC
Intervention: Biomarker studies
Study NCT04156373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fuerte
Description: Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
Study NCT01181427 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Blood Sample Collection
Description: See arm description
Study NCT01181427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytochrome P450 inhibitor
Description: See arm description
Study NCT02133118 — intervention group
Intervention type: DRUG
Intervention: individual SUs, insulin, pioglitazone
Study NCT03562273 — intervention group
Intervention type: RADIATION
Intervention: Quality Of Life Sizing Nomogram
Description: If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care.
Study NCT04364867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
Study NCT04364867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pain Pump
Description: Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
Study NCT02449122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional therapy
Description: Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
Study NCT02449122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
Study NCT02437916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 228
Description: AMG 228 will be administered intravenously
Study NCT00626106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 479
Description: AMG 479 administered with exemestane or fulvestrant
Study NCT00626106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered with either exemestane or fulvestrant
Study NCT03971903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention bias modification
Description: The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.
Study NCT03971903 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention bias modification
Description: The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.
Study NCT01574378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional closure
Description: non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
Study NCT01574378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Loc 90
Description: 2-layer wound closure using V-Loc 90 barbed suture
Study NCT01763801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P-Max
Description: tip placement in correspondence to the P-Max on the ECG
Study NCT01763801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P-Submax
Description: tip placement in correspondence to the P-Submax on the ECG
Study NCT04315259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: irrigation activated by diode laser versus soft tissue laser application therapy
Study NCT02884895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Tube Suction
Description: Intubating Laryngeal Tube Suction Disposable
Study NCT02884895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Direct Laryngoscopy
Study NCT02424734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline Fosamil
Description: Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).
Study NCT02424734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin
Description: Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.
Study NCT02424734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoglycoside
Description: Optional, will be given as per local standard of care.
Study NCT03387670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: * One (1 = 40mg) simvastatin tablet once daily at night for 1 month~* Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 to 53 months
Study NCT03387670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * One (1) placebo tablet once daily at night for 1 month~* Two (2) placebo tablets once daily at night, for the next 35 to 53 months
Study NCT00948064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
Study NCT00948064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
Study NCT00379015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00379015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00379015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00379015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Study NCT00379015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00379015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT01043575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: During the first 8 weeks of therapy for TB participants > 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants \< 45 kg participants will receive 450 mg orally given 5 days per week
Study NCT01043575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
Study NCT03432325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Enabled Prosthesis
Description: Surgically implanted neural enabled prosthesis
Study NCT03991780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
Study NCT03840317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19-targeting CAR T cells
Description: Autologous CD19-targeting CAR T cells
Study NCT00782535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single therapeutic dose
Study NCT00782535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single supratherapeutic dose
Study NCT00782535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled solution, single dose of placebo
Study NCT02031575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Treatment
Description: Mobile phone text messaging service about reproductive health
Study NCT02031575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Treatment
Description: Mobile phone text messaging service about reproductive health
Study NCT02031575 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control, comparator arm
Study NCT02558959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT02558959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02558959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT01414634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion
Study NCT05354661 — intervention group
Intervention type: DEVICE
Intervention: Hypotension Prediction Index
Description: treatment of hypotension before the appearance following HPI algorithm
Study NCT03046186 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed meal test with double tracer technique
Study NCT00232765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER Sirolimus-Eluting Stent
Description: CYPHER Sirolimus-Eluting Stent
Study NCT00232765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated BX VELOCITY Balloon-Expandable Stent
Description: Uncoated BX VELOCITY Balloon-Expandable Stent
Study NCT03043014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifépristone versus Misoprostol
Description: The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
Study NCT03043014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifépristone versus Misoprostol
Description: The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
Study NCT00848809 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: 9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
Study NCT00848809 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: 10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
Study NCT03985930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distraction with virtual reality
Description: Distraction content delivered through virtual reality goggles
Study NCT03985930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual
Study NCT02632799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHF small cannula
Description: NHF 8 l/min by Airvo 2 by small cannula
Study NCT02632799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHF big cannula
Description: NHF 8 l/min by Airvo 2 by large cannula
Study NCT02632799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Nsal CPAP 5cm H2o by face mask
Study NCT03877276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites
Study NCT03877276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spinach smoothie
Description: a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach
Study NCT03877276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kale smoothie
Description: prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale
Study NCT03877276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blended smoothie
Description: a prepared blended smoothie, consisting of banana, avocado, and orange juice
Study NCT03877276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: V spinach smoothie
Description: a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach
Study NCT03877276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium oxalate drink
Description: a prepared sodium oxalate drink
Study NCT02061787 — intervention group
Intervention type: DEVICE
Intervention: balloon pulmonary angioplasty
Description: patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty
Study NCT00490087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (IUD)
Study NCT04142203 — intervention group
Intervention type: OTHER
Intervention: 23 h surgery
Description: Patients were treated in 23 surgical unit
Study NCT01584232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Study NCT01584232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Study NCT01584232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylureas (SU)
Study NCT01584232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylureas (SU)
Study NCT01584232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biguanide (BG)
Study NCT01584232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biguanide (BG)
Study NCT02125396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]
Study NCT02125396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]
Study NCT02125396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Adjuvant radiotherapy is used for postoperative curative HCC
Study NCT00116753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
Study NCT00116753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
Study NCT00116753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
Study NCT02125396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Adjuvant radiotherapy is used for postoperative curative HCC
Study NCT03795571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2，d0